I would like to know the behaviors that have been adopted in your service in cases of bone marrow transplantation from RhD + patient, RhD- donor for transfusion of platelet concentrate.
Is there a concern to provide RhD- since the infusion?
Or after the patient only presents donor phenotyping RhD-?
In the impossibility of providing RhD-, have hemotherapists indicated anti-D prophylaxis?